TABLE 2.
Comprehensive analysis of QuantiFERON-TB Gold Plus discrepant casesh
| Case | Age (yr) | Gender | Setting | QFT CLIA (IU/ml) |
QFT ELISA (IU/ml) |
No. of lymphocytes (×109/liter)a | Relevant clinical historyg | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resultf | NIL | TB1-NIL | TB2-NIL | MIT-NIL | Resultf | NIL | TB1-NIL | TB2-NIL | MIT-NIL | ||||||
| 1 | 49 | M | Outpatient | P* | 0.03 | 0.10 | 0.42 | 10.00 | N | 0.03 | 0.04 | 0.04 | 8.78 | 2.33 | Tuberculosis contactb |
| 2 | 47 | F | Outpatient | P* | 0.15 | 0.25 | 0.57 | 10.00 | N* | 0.10 | 0.11 | 0.30 | 7.86 | 1.97 | Multiple sclerosis |
| 3 | 56 | F | HCW | I | 9.07 | 10.00 | 10.00 | 10.00 | N | 7.58 | 1.03 | 1.03 | 1.03 | ND | Nonec |
| 4 | 54 | M | Hospitalized | N | 0.01 | 0.10 | 0.16 | 0.55 | I | 0.03 | 0.00 | 0.00 | 0.36 | 1.17 | Severe COVID-19** |
| 5 | 70 | M | Hospitalized | N | 0.02 | −0.01 | −0.01 | 0.63 | I | 0.06 | −0.04 | −0.04 | 0.31 | 0.32 | Severe COVID-19** |
| 6 | 81 | F | Hospitalized | N | 0.05 | −0.00 | −0.00 | 1.09 | I | 0.03 | 0.00 | 0.00 | 0.43 | 0.53 | Severe COVID-19** |
| 7 | 47 | F | Hospitalized | N | 0.00 | 0.00 | 0.11 | 0.56 | I | 0.03 | −0.01 | 0.00 | 0.28 | 0.38 | Severe COVID-19** and history of kidney transplant |
| 8 | 23 | F | Hospitalized | P | 0.24 | 0.78 | 0.98 | 10.00 | N* | 0.08 | 0.21 | 0.30 | 6.22 | 1.13 | Tuberculous pleurisyd |
| 9 | 76 | M | Hospitalized | P* | 0.01 | 0.30 | 0.39 | 1.24 | N | 0.02 | 0.19 | 0.15 | 0.68 | 2.06 | Severe COVID-19** |
| 10 | 73 | M | Hospitalized | N | 0.03 | 0.00 | 0.01 | 0.56 | I | 0.03 | −0.01 | −0.01 | 0.49 | ND | Severe COVID-19** |
| 11 | 64 | F | Outpatient | N | 0.02 | 0.06 | −0.00 | 0.64 | I | 0.01 | 0.00 | 0.00 | 0.37 | 2.46 | None |
| 12 | 65 | F | Outpatient | P* | 0.10 | 0.40 | 0.53 | 10.00 | N* | 0.03 | 0.15 | 0.23 | 7.57 | ND | Psoriasis, tuberculosis contact |
| 13 | 42 | M | Hospitalized | N | 0.00 | 0.01 | 0.01 | 0.78 | I | 0.01 | 0.00 | 0.00 | 0.47 | 0.84 | Severe COVID-19** |
| 14 | 56 | F | Hospitalized | N | 0.02 | 0.02 | 0.02 | 0.50 | I | 0.03 | 0.00 | 0.00 | 0.13 | ND | Non-COVID-19-related pneumonia, SLEe |
| 15 | 53 | F | HCW | P* | 0.04 | 0.38 | 0.20 | 10.00 | N* | 0.04 | 0.27 | 0.13 | 10.00 | 1.66 | None |
Lymphocyte count was determined at the time of the QuantiFERON-TB Gold Plus test.
Individual under treatment with Rifinah, following prior diagnosis of latent tuberculous infection.
Individual with history of diagnosis of latent tuberculous infection.
Patient under a 7-day treatment with Rimstar, following prior diagnosis of active tuberculosis.
Chronic disease patient under treatment with immunosuppressive drugs. Additionally, the individual had a history of conversion (defined as having a positive test that followed a negative one) by QuantiFERON-TB Gold Plus test.
*, borderline results (equivocal range between 0.20 and 0.70 IU/ml).
**, most severe COVID-19 patients were under treatment with immunosuppressive drugs (corticosteroids, tocilizumab, anakinra, etc.) at the time of the QuantiFERON-TB Gold Plus test.
Abbreviations: IU, international units; CLIA, chemiluminescence immunoassay; ELISA, enzyme-linked immunosorbent assay; MIT, mitogen; M, male; F, female; HCW, health care worker; P, positive; N, negative; I, indeterminate; ND, not determined; SLE, systemic lupus erythematosus.